drugset / Trial / NCT02636361

A Study of Various Formulations of LY900014 in Healthy Participants

NCT02636361

Phase 1 Completed 26 enrolled Eli Lilly and Company
RandomizedCrossoverSingle-blindBasic science

Summary

This study will evaluate how quickly the body absorbs, breaks down, and gets rid of the different formulations of LY900014. This study will determine how the different formulations, when injected under the skin, will affect the blood sugar levels in the body, and how safe it is.

Timeline

Start
2015-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.